Apontis Pharma AG
XETRA:APPH
Operating Margin
Apontis Pharma AG
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| DE |
A
|
Apontis Pharma AG
XETRA:APPH
|
93.7m EUR |
-14%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
793.6B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
393.8B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.3T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
246.5B CHF |
32%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
235.8B USD |
36%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
180B GBP |
23%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
200.9B CHF |
32%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
166.1B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
148.9B USD |
25%
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Apontis Pharma AG's most recent financial statements, the company has Operating Margin of -13.6%.
You don't have any saved screeners yet